UBS forecasts that Sandoz will likely achieve the lower end of its 24-26% core EBITDA margin target by 2028. To reach the ...

A HEARTBROKEN mum says she “nearly died” hearing her little girl’s diagnosis – after the tot’s face kept swelling following a ...

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

Patients with CKD who use antiresorptive drugs for tumor-related disorders or oral corticosteroids may be at increased risk for osteonecrosis of the jaw.

US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

January saw almost every major cardiovascular subspecialty represented among our most-clicked stories of the month.

Novartis' soon-to-be-divested Sandoz unit has positive clinical trial data in hand for a biosimilar of Amgen's blockbuster osteoporosis therapy Prolia (denosumab), clearing the way for regulatory ...